GLP Receptor

The GLP receptors contain two family members, GLP-1 receptor (GLP1R, or GLP-1R) and GLP-2 receptor (GLP2R or GLP-1R), activated by the glucagon-like peptides (GLPs). GLPs are s secreted by intestinal cells; causes insulin release; inhibits glucagon secretion, appetite, and energy intake; and delays gastric emptying because GLP receptors are located on the gut, pancreas, brainstem, hypothalamus, and vagal-afferent nerves. GLP-1 has only one known receptor, GLP1R, and regulates gut motility, appetite, islet function, and glucose homeostasis, whereas GLP-2, the agonist of GLP2R, enhances intestinal nutrient absorption. GLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome. An investigation of the actions of GLP receptor activation on gallbladder motility has demonstrated that GLP-2 receptor activation increases gallbladder volume in vivo and decreases spontaneous activity in GBSM bundles ex vivo. Like the inhibitory transmitters, which elicit their actions via an adenylate cyclase-protein kinase A-KATP channel pathway, the GLP-2 receptor signals through this same pathway.

GLP Receptor Related Products (111)
Antibodies (1)

By Effects:	Controls (2) Inhibitors (3) Agonists (70) Degrader (1) Antagonists (7) Activators (3) Modulators (8)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P990990

Efsubaglutide alfa
HY-P990990 is an GLP-1 receptor-targeting Fusion Protein.

HY-P990967

Sonefpeglutide
HY-P990967 is an GLP1R-targeting human antibody.

HY-P5161

FC382K10W15	Agonist
FC382K10W15 is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 can be used in type 2 diabetes research.

HY-P10318

SHR-2042	Antagonist
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency.

HY-143312C

(S)-V-0219	Modulator
(S)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice.

HY-162306

GLP-1R agonist 18	Agonist
GLP-1R agonist 18 (example 117) is an agonist for GLP-1R with an EC₅₀ of 0.044 nM.

HY-P10591

Olatorepatide	Agonist
Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect.

HY-P0264A

Exendin(9-39) amide acetate	Antagonist
Exendin(9-39) amide (Avexitide) acetate is a glucagon-like peptide-1 (GLP-1) antagonist that competes with endogenous GLP-1 for the GLP-1R, counteracting the effects of excessive GLP-1 secretion. Exendin(9-39) amide acetate can be utilized in Postbariatric hypoglycemia (PBH) research.

HY-147628

GLP-1R agonist 15	Agonist
GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist.

HY-162436

GLP-1R agonist 21	Agonist
GLP-1R agonist 21 (Compound I-134) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC₅₀ of 0.0104 nM.

HY-P5161A

FC382K10W15 TFA	Agonist
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research.

HY-160031

GLP-1R agonist 19	Agonist
GLP-1R agonist 19 (M3190) is a potent and selective GLP-1R agonist. GLP-1R agonist 19 has excellent plasma stability, liver microsomal stability, and low hERG toxicity.

HY-162435

GLP-1R agonist 20	Agonist
GLP-1R agonist 20 (Compound I-132) is an agonist for glucagon-like peptide-1 receptor (GLP-1 receptor), with EC₅₀ of 0.0162 nM.

HY-P10327

PP18	Agonist
PP18 is a novel OXM-based dual GLP-1 and glucagon receptor agonist with EC₅₀ values of 0.487 nM target hGLP-1R and 0.188 nM target hGcgR.

HY-168481

GLP-1R agonist 27	Agonist
GLP-1R agonist 27 (compound 21) is a potent and orally active GLP-1R agonist. GLP-1R agonist 27 promots cyclic adenosine monophosphate (cAMP) accumulation. GLP-1R agonist 27 reduces blood glucose levels and food intake. GLP-1R agonist 27 has the potential for the research of obesity and type 2 diabetes mellitus (T2DM).

HY-143312B

(R)-V-0219	Modulator
(R)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (R)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R.

HY-120828

Albenatide	Agonist
Albenatide (CJC 1134PC) is a modified Exendin-4 (HY-13443) analogue conjugated to human recombinant albumin (HRA) in vitro to form a long-acting DPP-4-resistant GLP-1R agonist. Albenatide covalently binds through a low-molecular chemical linker (cys-C13H19O6N3-lys) to the cysteine residue in position 34 of HRA. Albenatide increases cyclic AMP (cAMP) production in vitro. Albenatide reduces glucose excursions, food intake, gastric emptying in wild-type mice and improves glucose tolerance and reduces body weight in high-fat diet mice.

HY-147629

GLP-1R agonist 16	Agonist
GLP-1R agonist 16 (Compound 115a) is a GLP-1 receptor agonist with an EC₅₀ of 0.15 nM.

HY-147627

GLP-1R agonist 14	Agonist
GLP-1R agonist 14 (Compound 14) is a GLP-1 receptor agonist with an EC₅₀ of 0-20 nM against h-GLP-1.

HY-170831

DS79932728	Antagonist
DS79932728 is an orally active inhibitor for G9a and GLP with IC₅₀ of 12.6 nM and 75.7 nM. DS79932728 induces the production of γ-globin, thereby increasing the level of fetal hemoglobin (HbF). DS79932728 increases F-reticulocytes (F-rets) proportion and exhibits good oral absorption characteristics in cynomolgus monkey models.

Name
Email *

	Sorry, but the email address you supplied was invalid.

GLP Receptor

GLP Receptor Related Products (111)

Antibodies (1)

GLP Receptor Related Products (111):